NeoGenomics Inc (NEO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NeoGenomics Inc (NEO) has a cash flow conversion efficiency ratio of -0.010x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.14 Million) by net assets ($828.76 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check asset allocation strategy of NeoGenomics Inc to assess the company's strategic physical and investment asset allocation.
NeoGenomics Inc - Cash Flow Conversion Efficiency Trend (2000–2025)
This chart illustrates how NeoGenomics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. See NEO total equity for net asset value and shareholders' equity analysis.
NeoGenomics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NeoGenomics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Olema Pharmaceuticals Inc
NASDAQ:OLMA
|
-0.080x |
|
FAWER Automotive Parts Ltd Co
SHE:000030
|
0.027x |
|
Sitronix Technology Corp
TW:8016
|
0.075x |
|
Netcare
JSE:NTC
|
0.220x |
|
Zhejiang Taihua New Material
SHG:603055
|
0.059x |
|
Avino Silver & Gold Mines Ltd
TO:ASM
|
0.043x |
|
Zhejiang Jingxing Paper Joint Stock Co Ltd
SHE:002067
|
0.019x |
|
TPK Holding Co Ltd
TW:3673
|
-0.015x |
Annual Cash Flow Conversion Efficiency for NeoGenomics Inc (2000–2025)
The table below shows the annual cash flow conversion efficiency of NeoGenomics Inc from 2000 to 2025. For the full company profile with market capitalisation and key ratios, see market value of NeoGenomics Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $836.56 Million | $5.23 Million | 0.006x | -19.68% |
| 2024-12-31 | $902.34 Million | $7.02 Million | 0.008x | +475.22% |
| 2023-12-31 | $941.54 Million | $-1.95 Million | -0.002x | +96.86% |
| 2022-12-31 | $998.02 Million | $-65.99 Million | -0.066x | -174.23% |
| 2021-12-31 | $1.11 Billion | $-26.72 Million | -0.024x | -1246.64% |
| 2020-12-31 | $694.29 Million | $1.46 Million | 0.002x | -95.43% |
| 2019-12-31 | $507.41 Million | $23.37 Million | 0.046x | -67.05% |
| 2018-12-31 | $320.44 Million | $44.79 Million | 0.140x | +59.26% |
| 2017-12-31 | $205.53 Million | $18.04 Million | 0.088x | -23.75% |
| 2016-12-31 | $186.60 Million | $21.48 Million | 0.115x | +328.69% |
| 2015-12-31 | $238.11 Million | $6.39 Million | 0.027x | -82.84% |
| 2014-12-31 | $60.41 Million | $9.45 Million | 0.156x | +52.52% |
| 2013-12-31 | $21.71 Million | $2.23 Million | 0.103x | +292.14% |
| 2012-12-31 | $9.22 Million | $-492.00K | -0.053x | -556.25% |
| 2011-12-31 | $5.90 Million | $69.00K | 0.012x | +101.79% |
| 2010-12-31 | $3.13 Million | $-2.05 Million | -0.655x | -146.19% |
| 2009-12-31 | $5.64 Million | $-1.50 Million | -0.266x | -188.57% |
| 2008-12-31 | $1.50 Million | $-138.31K | -0.092x | +91.90% |
| 2007-12-31 | $2.32 Million | $-2.64 Million | -1.138x | +91.06% |
| 2006-12-31 | $54.51K | $-693.78K | -12.727x | -1503.72% |
| 2005-12-31 | $-994.94K | $-902.05K | 0.907x | -41.22% |
| 2004-12-31 | $-426.65K | $-658.13K | 1.543x | +6.57% |
| 2003-12-31 | $-367.80K | $-532.37K | 1.447x | +108.78% |
| 2002-12-31 | $23.34K | $-384.80K | -16.483x | -2333.16% |
| 2001-12-31 | $-104.87K | $-77.41K | 0.738x | -47.98% |
| 2000-12-31 | $-124.84K | $-177.13K | 1.419x | -- |
About NeoGenomics Inc
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to dise… Read more